18Oct 2018

CHOLESTEROL MYTH FROM SCRUPULOSITY IN THE 1953 TO CERTITUDE IN 2018.

  • Senior Consultant Congenital Cardiologist, Electrophysiologist,Director of Research & Biostatistics Administration World Gold Medal Awardee(WOSCO-2012) Prince Sultan Cardiac Centre-Alhassa-Saudi Arabia.
Crossref Cited-by Linking logo
  • References
  • Cite This Article as
  • Corresponding Author
  1. Scherst?n T, Rosch PJ, Arfors KE, Sundberg R. The cholesterol hypothesis: time for the obituary? Scand Cardiovasc J. 2011 Dec;45(6):322-3.
  2. Alabdulgader Abdullah, Global Consciousness and The Great Cholesterol Myth (from1800s to 2018): Wisdom Must Prevail. Review paper under press.
  3. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 1966 Oct;34(4):679-97.
4.?????? KEYS A. Atherosclerosis: a problem in newer public health. J Mt Sinai Hosp NY. 1953 Jul-Aug;20(2):118-39.5.?????? Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, Djordjevic BS, Dontas AS, Fidanza F, Keys MH, et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol. 1986 Dec;124(6):903-15.6.?????? Yersushalmay J, Hilleboe HE.Fat in the diet and mortality from heart disease;a methodologic note. N Y State J Med. 1957 Jul 15;57(14):2343-54.7.?????? Diamond DM, Ravnskov U. How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Rev Clin Pharmacol. 2015 Mar;8(2):201-10.
  1. Alabdulgader Abdullah; The Major Chloestrol Myth: ,Proceedings of King of Organs Interrnational Conferences for Advanced Cardiac Sciences (2006,2008,1010,2012), ISBN 978-9952-451-29-0, World Organization for Scientific Cooperation (WOSCO) Part 2,Munich ,Germany,2017.
  2. Alabdulgader Abdullah (2016) Future of cardiovascular practice: Alert to change or call for revolution.. J Cardiovasc Med Ther. 2017;1(1):1.
  3. Ravnskov U. A hypothesis out-of-date. the diet-heart idea. J Clin Epidemiol.2002 Nov;55(11):1057-63.
  4. Lindholm LH, Samuelsson O; ASCOT. What are the odds at ASCOT today? Lancet.2003 Apr 5;361(9364):1144-5.
  5. Thompson A, Temple NJ. The case for statins: has it really been made? J R Soc Med. 2004 Oct;97(10):461-4.
  6. Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskj?ld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open. 2016 Jun 12;6(6):e010401.
  7. Zimetbaum P, Frishman WH, Ooi WL, Derman MP, Aronson M, Gidez LI, Eder HA.Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly. The Bronx Aging Study. Arterioscler Thromb. 1992 Apr;12(4):416-23.
  8. Akerblom JL, Costa R, Luchsinger JA, Manly JJ, Tang MX, Lee JH, Mayeux R, Schupf N. Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders. Age Ageing. 2008 Mar;37(2):207-13.
  9. Bathum L, Depont Christensen R, Engers Pedersen L, Lyngsie Pedersen P, Larsen J, Nex?e J. Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-base register study. Scand J Prim Health Care. 2013 Sep; 31(3):172-80.
  10. Lv YB, Yin ZX, Chei CL, Qian HZ, Kraus VB, Zhang J, Brasher MS, Shi XM, Matchar DB, Zeng Y. Low-density lipoprotein cholesterol was inversely associated with 3-year all-cause mortality among Chinese oldest old: data from the Chinese Longitudinal Healthy Longevity Survey. Atherosclerosis. 2015 Mar;239(1):137-42.
  11. David Nunan, Dylan Collins, Nikolas Bobrovitz, Kamal R. Mahtani. CEBM response: ?Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review? ? a post publication peer review. June 13, 2016
  12. https://www.cebm.net/2016/06/cebm-response-lack-association-inverse-association-low-density-lipoprotein-cholesterol-mortality-elderly-systematic-review-post-publication-pee/. Accessed on 25/09/2018.
  13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002 Jul 6;360(9326):7-22.
  14. Sever PS, Dahl?f B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64 Suppl 2:43-60.
  15. de Lorgeril M, Rabaeus M. Beyond Confusion and Controversy, Can We Evaluate the Real Efficacy and Safety of Cholesterol-Lowering with Statins?. Journal of Controversies in Biomedical Research 2015;1(1)
  16. Huang SS, Liu IH, Chen CL, Chang JM, Johnson FE, Huang JS. 7-Dehydrocholesterol (7-DHC), But Not Cholesterol, Causes Suppression of Canonical TGF-β Signaling and Is Likely Involved in the Development of Atherosclerotic Cardiovascular Disease (ASCVD). J Cell Biochem. 2017 Jun;118(6):1387-1400.
  17. Choi SH, Chae A, Miller E, Messig M, Ntanios F, DeMaria AN, Nissen SE, Witztum JL, Tsimikas S. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma:volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol. 2008 Jul 1;52(1):24-32.
  18. Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99.
  19. Luo W, He Y, Ding F, Nie X, Li XL, Song HL, Li GX. Study on the levels of glycosylated lipoprotein in patients with coronary artery atherosclerosis. J Clin Lab Anal. 2018 Aug 12:e22650.
  20. Tabas I, Williams KJ, Bor?n J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007 Oct 16;116(16):1832-44.
  21. Hamazaki T, Okuyama H, Ogushi Y, Hama R. Towards a Paradigm Shift in Cholesterol Treatment. A Re-examination of the Cholesterol Issue in Japan. Ann Nutr Metab. 2015;66 Suppl 4:1-116.

[Abdullah Alabdulagader. (2018); CHOLESTEROL MYTH FROM SCRUPULOSITY IN THE 1953 TO CERTITUDE IN 2018. Int. J. of Adv. Res. 6 (Oct). 1237-1242] (ISSN 2320-5407). www.journalijar.com


Abdullah Alabdullagader
Research & Biostatistics Administration Prince Sultan Cardiac Centre-Alhassa-Saudi Arabia

DOI:


Article DOI: 10.21474/IJAR01/7930      
DOI URL: http://dx.doi.org/10.21474/IJAR01/7930